Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.59 -0.6%	$19.29	$10.21 ▼ $25.67	$4.22B	0.43	3.66 million shs	3.04 million shs
CYTK Cytokinetics	$38.89 +0.5%	$33.08	$29.31 ▼ $61.38	$4.62B	0.59	1.53 million shs	1.53 million shs
PCVX Vaxcyte	$37.37 +2.2%	$33.74	$27.66 ▼ $121.06	$4.72B	1.19	1.49 million shs	1.25 million shs
PROK ProKidney	$3.52 -5.6%	$1.28	$0.46 ▼ $7.13	$1.09B	1.26	3.58 million shs	7.43 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-0.57%	-4.76%	-6.88%	-17.46%	+32.36%
CYTK Cytokinetics	+0.54%	+6.29%	+19.51%	-1.49%	-31.52%
PCVX Vaxcyte	+2.19%	+3.12%	+11.09%	+21.92%	-54.07%
PROK ProKidney	-5.63%	-32.05%	+310.30%	+345.06%	+53.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8847 of 5 stars	3.7	1.0	0.0	2.9	2.5	3.1
CYTK Cytokinetics	4.0516 of 5 stars	4.5	1.0	4.6	2.1	0.8	0.0
PCVX Vaxcyte	1.8181 of 5 stars	3.6	1.0	0.0	2.5	1.7	0.0
PROK ProKidney	3.3858 of 5 stars	3.2	4.0	0.0	3.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	57.29% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	82.37% Upside
PCVX Vaxcyte	3.10	Buy	$136.50	265.27% Upside
PROK ProKidney	2.40	Hold	$6.25	77.56% Upside

Current Analyst Ratings Breakdown

Latest PROK, PCVX, ADMA, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00
5/14/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
5/13/2025	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/8/2025	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $53.00
5/7/2025	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$82.00 ➝ $80.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.85	$0.54 per share	32.68	$1.48 per share	11.89
CYTK Cytokinetics	$18.47M	251.47	N/A	N/A	($1.15) per share	-33.82
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A
PROK ProKidney	$80K	12,878.80	N/A	N/A	($3.41) per share	-1.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	20.69	25.49	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)

Latest PROK, PCVX, ADMA, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CYTK Cytokinetics	-$1.32	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	PROK ProKidney	-$0.14	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PCVX Vaxcyte	-$1.12	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
CYTK Cytokinetics	N/A	5.99	5.99
PCVX Vaxcyte	N/A	17.70	17.70
PROK ProKidney	N/A	10.96	10.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
CYTK Cytokinetics	N/A
PCVX Vaxcyte	96.78%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
CYTK Cytokinetics	2.70%
PCVX Vaxcyte	3.10%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable

PROK, PCVX, ADMA, and CYTK Headlines

Recent News About These Companies

ProKidney Corp. (NASDAQ:PROK) Receives $5.67 Average Price Target from Analysts

1 hour ago | americanbankingnews.com

PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 17 at 1:01 PM | zacks.com

Best Momentum Stocks to Buy for July 17th

July 17 at 11:01 AM | zacks.com

New Strong Buy Stocks for July 17th

July 17 at 6:40 AM | zacks.com

ProKidney gains pivotal therapy advancement step with FDA

July 17 at 6:15 AM | journalnow.comJ

ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?

July 16 at 1:01 PM | zacks.com

ProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst Upgrade

July 16 at 2:18 AM | americanbankingnews.com

ProKidney (NASDAQ:PROK) Shares Gap Up on Analyst Upgrade

July 16 at 2:27 AM | americanbankingnews.com

Promising clinical trial results give ProKidney share price major boost

July 15 at 11:46 PM | journalnow.comJ

ProKidney stock soars after FDA confirms accelerated approval pathway

July 15 at 11:46 PM | in.investing.com

ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial

July 15 at 11:46 PM | marketwatch.com

ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy

July 15 at 11:46 PM | msn.com

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

July 15 at 11:46 PM | finance.yahoo.com

ProKidney (NASDAQ:PROK) Trading 7.5% Higher After Analyst Upgrade

July 15 at 11:57 AM | marketbeat.com

ProKidney Corp. (NASDAQ:PROK) Receives Average Recommendation of "Hold" from Brokerages

July 15 at 11:53 AM | marketbeat.com

ProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and Diabetes

July 15 at 7:46 AM | quiverquant.comQ

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

July 15 at 7:30 AM | globenewswire.com

ProKidney (NASDAQ:PROK) Shares Gap Up Following Analyst Upgrade

July 14, 2025 | marketbeat.com

Guggenheim Increases ProKidney (NASDAQ:PROK) Price Target to $7.00

July 14, 2025 | marketbeat.com

Promising clincial trial results give ProKidney share price major boost

July 14, 2025 | greensboro.comG

ProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?

July 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, PCVX, ADMA, and CYTK Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.59 -0.10 (-0.57%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$17.60 +0.01 (+0.06%)

As of 07/17/2025 07:57 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Cytokinetics NASDAQ:CYTK

$38.89 +0.21 (+0.54%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$38.60 -0.29 (-0.76%)

As of 07/17/2025 07:01 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Vaxcyte NASDAQ:PCVX

$37.37 +0.80 (+2.19%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$37.36 -0.01 (-0.03%)

As of 07/17/2025 04:20 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

ProKidney NASDAQ:PROK

$3.52 -0.21 (-5.63%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$3.56 +0.04 (+0.99%)

As of 07/17/2025 07:59 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time